Coherus Oncology Inc [CHRS] stock is trading at $1.31, up 3.97%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CHRS shares have gain 14.91% over the last week, with a monthly amount glided 43.92%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Coherus Oncology Inc [NASDAQ: CHRS] stock has seen the most recent analyst activity on September 04, 2025, when Maxim Group upgraded its rating to a Buy. Previously, UBS downgraded its rating to Neutral on August 16, 2024, and dropped its price target to $1.50. On November 17, 2023, Robert W. Baird initiated with a Outperform rating and assigned a price target of $11 on the stock. Maxim Group downgraded its rating to a Hold. Citigroup initiated its recommendation with a Buy and recommended $12 as its price target on July 24, 2023. Truist started tracking with a Buy rating for this stock on May 01, 2023, and assigned it a price target of $24. In a note dated March 28, 2023, UBS upgraded a Buy rating on this stock but restated the target price of $11.
Coherus Oncology Inc [CHRS] stock has fluctuated between $0.66 and $2.43 over the past year. Currently, Wall Street analysts expect the stock to reach $1.05 within the next 12 months. Coherus Oncology Inc [NASDAQ: CHRS] shares were valued at $1.31 at the most recent close of the market. An investor can expect a potential drop of -19.85% based on the average CHRS price forecast.
Analyzing the CHRS fundamentals
Coherus Oncology Inc [NASDAQ:CHRS] reported sales of 142.77M for the trailing twelve months, which represents a drop of -84.22%. Gross Profit Margin for this corporation currently stands at 0.57% with Operating Profit Margin at -0.98%, Pretax Profit Margin comes in at -1.08%, and Net Profit Margin reading is 1.26%. To continue investigating profitability, this company’s Return on Assets is posted at 0.41, Equity is -2.54 and Total Capital is -0.79. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2705 points at the first support level, and at 1.2311 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3697, and for the 2nd resistance point, it is at 1.4295.
Ratios To Look Out For
For context, Coherus Oncology Inc’s Current Ratio is 1.44. Also, the Quick Ratio is 1.43, while the Cash Ratio stands at 0.82. Considering the valuation of this stock, the price to sales ratio is 1.07, the price to book ratio is 1.27.
Transactions by insiders
Recent insider trading involved Wahlstrom Mats, Director, that happened on May 23 ’25 when 99988.0 shares were sold.
